{'fraction_non_alphanumeric': 0.016822429906542057, 'fraction_numerical': 0.003738317757009346, 'mean_word_length': 5.090909090909091, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of hyperlipidaemia. Why, when and how to treat.

For the last 50 years, there has been a seemingly endless debate in scientific, clinical and epidemiological journals and conferences round the world about the 'lipid hypothesis' and the role of cholesterol in the pathogenesis of coronary heart disease. Evidence accumulated in recent years has dispelled much of the earlier controversy and we can now conclude that the presence of atherogenic lipoproteins in the plasma is central to the causation of coronary heart disease.